title: Personalizing health care: feasibility and future implications
creator: Godman, Brian
creator: Finlayson, Alexander E.
creator: Cheema, Parneet K.
creator: Zebedin-Brandl, Eva
creator: Gutiérrez-Ibarluzea, Inaki
creator: Jones, Jan
creator: Malmström, Rickard E.
creator: Asola, Elina
creator: Baumgärtel, Christoph
creator: Bennie, Marion
creator: Bishop, Iain
creator: Bucsics, Anna
creator: Campbell, Stephen
creator: Diogene, Eduardo
creator: Ferrario, Alessandra
creator: Fürst, Jurij
creator: Garuoliene, Kristina
creator: Gomes, Miguel
creator: Harris, Katharine
creator: Haycox, Alan
creator: Herholz, Harald
creator: Hviding, Krystyna
creator: Jan, Saira
creator: Kalaba, Marija
creator: Kvalheim, Christina
creator: Laius, Ott
creator: Lööv, Sven-Ake
creator: Malinowska, Kamila
creator: Martin, Andrew
creator: McCullagh, Laura
creator: Nilsson, Fredrik
creator: Paterson, Ken
creator: Schwabe, Ulrich
creator: Selke, Gisbert
creator: Sermet, Catherine
creator: Simoens, Steven
creator: Tomek, Dominik
creator: Vlahovic-Palcevski, Vera
creator: Voncina, Luka
creator: Wladysiuk, Magdalena
creator: van Woerkom, Menno
creator: Wong-Rieger, Durhane
creator: Zara, Corrine
creator: Ali, Raghib
creator: Gustafsson, Lars L.
subject: ddc-610
subject: 610 Medical sciences Medicine
description: Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.
publisher: BioMed Central; Springer
date: 2013
type: Article
type: info:eu-repo/semantics/article
type: NonPeerReviewed
format: application/pdf
identifier: https://archiv.ub.uni-heidelberg.de/volltextserver/20215/1/12916_2013_Article_857.pdf
identifier: DOI:
identifier: urn:nbn:de:bsz:16-heidok-202158
identifier:   Godman, Brian ; Finlayson, Alexander E. ; Cheema, Parneet K. ; Zebedin-Brandl, Eva ; Gutiérrez-Ibarluzea, Inaki ; Jones, Jan ; Malmström, Rickard E. ; Asola, Elina ; Baumgärtel, Christoph ; Bennie, Marion ; Bishop, Iain ; Bucsics, Anna ; Campbell, Stephen ; Diogene, Eduardo ; Ferrario, Alessandra ; Fürst, Jurij ; Garuoliene, Kristina ; Gomes, Miguel ; Harris, Katharine ; Haycox, Alan ; Herholz, Harald ; Hviding, Krystyna ; Jan, Saira ; Kalaba, Marija ; Kvalheim, Christina ; Laius, Ott ; Lööv, Sven-Ake ; Malinowska, Kamila ; Martin, Andrew ; McCullagh, Laura ; Nilsson, Fredrik ; Paterson, Ken ; Schwabe, Ulrich ; Selke, Gisbert ; Sermet, Catherine ; Simoens, Steven ; Tomek, Dominik ; Vlahovic-Palcevski, Vera ; Voncina, Luka ; Wladysiuk, Magdalena ; van Woerkom, Menno ; Wong-Rieger, Durhane ; Zara, Corrine ; Ali, Raghib ; Gustafsson, Lars L.  (2013) Personalizing health care: feasibility and future implications.  BMC Medicine, 11 (179).  pp. 1-23.  ISSN 1741-7015     
relation: https://archiv.ub.uni-heidelberg.de/volltextserver/20215/
rights: info:eu-repo/semantics/openAccess
rights: Please see front page of the work (Sorry, Dublin Core plugin does not recognise license id)
language: eng